Lampson, B. L., Nishino, M., Dahlberg, S. E., Paul, D., Santos, A. A., Jänne MD, P. A., & Oxnard, G. R. (2016). Activity of erlotinib when dosed below maximum tolerable dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer.

Lampson, Benjamin L., Mizuki Nishino, Suzanne E. Dahlberg, Danie Paul, Abigail A. Santos, Pasi A. Jänne MD, und Geoffrey R. Oxnard. "Activity of Erlotinib When Dosed Below Maximum Tolerable Dose for EGFR-mutant Lung Cancer: Implications for Targeted Therapy Development." Cancer 2016.

Lampson, Benjamin L., et al. "Activity of Erlotinib When Dosed Below Maximum Tolerable Dose for EGFR-mutant Lung Cancer: Implications for Targeted Therapy Development." Cancer 2016.